Single-Blind, Randomized, Phase Iii b Study in Children Aged 1 - 11 Years to Investigate the Immunogenicity, Safety and Interchangeability of Two Tick-Borne Encephalitis (Tbe) Vaccines Administered According to a Conventional Schedule

Trial Profile

Single-Blind, Randomized, Phase Iii b Study in Children Aged 1 - 11 Years to Investigate the Immunogenicity, Safety and Interchangeability of Two Tick-Borne Encephalitis (Tbe) Vaccines Administered According to a Conventional Schedule

Completed
Phase of Trial: Phase III

Latest Information Update: 29 May 2015

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary) ; Aluminium hydroxide
  • Indications Encephalitis virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Baxter Healthcare Corporation; Pfizer
  • Most Recent Events

    • 02 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 02 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Results reported in Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top